NutriBand (NTRB) Cost of Revenue (2018 - 2026)
NutriBand (NTRB) posted Cost of Revenue of $236598.0 for Q2 2026, down 24.11% sequentially from $311768.0 in Q1 2026, and down 43.05% YoY from $415451.0 in Q2 2025.
NutriBand (NTRB) Cost of Revenue (2018 - 2026) Analysis & Trends
NutriBand has reported Cost of Revenue for 9 years, with the latest figure at $236598.0 in Q2 2026.
- Quarterly Cost of Revenue fell 43.05% year-over-year to $236598.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.3 million (down 17.63% YoY) and the FY2026 annual result came in at $1.5 million, up 5.31% from the prior year.
- Cost of Revenue fell to $236598.0 in Q2 2026 per NTRB's latest filing, from $311768.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $465571.0 in Q3 2025 and troughed at $236598.0 in Q2 2026.
- A 5-year average of $330895.2 and a median of $326520.0 in 2024 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2025 and 2026: Cost of Revenue jumped 70.44% in 2025, then slumped 43.05% in 2026.
- Over 5 years, Cost of Revenue stood at $349272.0 in 2022, then declined by 23.01% to $268920.0 in 2023, then jumped by 69.11% to $454767.0 in 2024, then slumped by 38.97% to $277553.0 in 2025, then slipped by 14.76% to $236598.0 in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $236598.0, $311768.0, and $277553.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | 236,598.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 236,598.00 |
| Apr 30, 2026 | 236,598.00 |
| Jan 31, 2026 | 311,768.00 |
| Jan 31, 2026 | 311,768.00 |
| Oct 31, 2025 | 277,553.00 |
| Oct 31, 2025 | 277,553.00 |
| Jul 31, 2025 | 465,571.00 |
| Jul 31, 2025 | 465,571.00 |
| Apr 30, 2025 | 415,451.00 |
| Apr 30, 2025 | 415,451.00 |
| Jan 31, 2025 | 356,435.00 |
| Jan 31, 2025 | 356,435.00 |
| Oct 31, 2024 | 454,767.00 |
| Oct 31, 2024 | 454,767.00 |
| Jul 31, 2024 | 341,272.00 |
| Jul 31, 2024 | 341,272.00 |
| Apr 30, 2024 | 243,746.00 |
| Apr 30, 2024 | 243,746.00 |
| Jan 31, 2024 | 343,385.00 |
| Jan 31, 2024 | 343,385.00 |